SCHEDULE: Highbridge Capital Trims SELLAS Life Sciences Stake to 3.7%

Highbridge Capital Management has reduced its beneficial ownership in SELLAS Life Sciences Group, Inc. from 6.0% to 3.7% through warrant exercises.

Summary

• Highbridge Capital Management, LLC, an investment adviser, has filed an Amendment No. 2 to its Schedule 13G regarding its beneficial ownership in SELLAS Life Sciences Group, Inc.
• As of the filing date (January 30, 2026), Highbridge beneficially owns 6,514,658 shares of Common Stock, representing 3.7% of the class.
• These shares are issuable upon the exercise of warrants held by the Highbridge Funds.
• This represents a decrease from the 9,014,658 shares (6.0% of the class) beneficially owned as of December 31, 2025.
• The percentage calculation for the current ownership (3.7%) is based on 170,282,026 shares of Common Stock outstanding as of January 7, 2026.
• The previous percentage calculation (6.0%) was based on 142,442,239 shares outstanding as of November 11, 2025.
• Highbridge Capital Management, LLC is a Delaware limited liability company and acts as an investment adviser to certain funds and accounts.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a moderately negative signal. A significant reduction in beneficial ownership by an institutional investor like Highbridge Capital Management, even if passive, can suggest a diminished conviction or a reallocation of capital, which may concern other investors.

Positives

• NA

Negatives

• Highbridge Capital Management's beneficial ownership in SELLAS Life Sciences Group, Inc. has decreased from 6.0% as of December 31, 2025, to 3.7% as of January 30, 2026, indicating a reduction in their stake.

Risks

• NA

Future Outlook

NA

Management Comments

• Highbridge Capital Management, LLC certifies that, to the best of its knowledge and belief, the securities were acquired and are held in the ordinary course of business and not for the purpose or with the effect of changing or influencing the control of the issuer, nor in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

StockSavvy.ai notes that a reduction in beneficial ownership by a significant institutional investor like Highbridge Capital Management in a life sciences company can sometimes signal a shift in investment strategy or a re-evaluation of the company's prospects. While a Schedule 13G filing does not provide reasons for the change, such movements are closely watched by the market, particularly in the volatile biotechnology sector where investor confidence plays a crucial role.

Stakeholder Impact

• Shareholders may view the reduction in Highbridge Capital Management's stake as a negative indicator, potentially leading to decreased investor confidence or selling pressure on the stock.
• The company's management might need to address investor concerns regarding the change in institutional ownership.

Key Dates

Recommendation

While the reduction in Highbridge Capital Management's stake is a negative signal, a Schedule 13G filing alone does not provide sufficient fundamental information about SELLAS Life Sciences Group, Inc. to warrant a 'sell' recommendation. Investors should 'hold' and await further financial disclosures or operational updates from the company to understand the broader context of this ownership change and its potential implications for the company's valuation and future prospects. The decrease in ownership could be due to various factors not disclosed in this filing, such as portfolio rebalancing or warrant expiration, rather than a direct negative assessment of SELLAS's fundamentals.

Keywords

SELLAS Life Sciences Group, Highbridge Capital Management, Beneficial Ownership, Schedule 13G, Common Stock, Warrants, Institutional Investor, Biotechnology, Pharmaceuticals